Efficacy of quadruple therapy for Helicobacter pylori eradication after failure of proton pump inhibitor-based triple therapy in Singapore

Chinese Journal of Digestive Diseases

Volumn 4, Issue 1, 2003, Pages 35-39

  Ang, Tiing Leong ^a   Fock, K M ^a   Ng, T M ^a   Teo, E K ^a   Chua, T S ^a   Tan, Y L ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Helicobacter pylori; Quadruple Therapy; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; UREASE;

ADULT; AGED; ARTICLE; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DRUG EFFICACY; DUODENOSCOPY; ENZYME ASSAY; ERADICATION THERAPY; ESOPHAGOSCOPY; FEMALE; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; SINGAPORE; TREATMENT FAILURE; UREA BREATH TEST;

EID: 0037502296     PISSN: 14439611     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1443-9573.2003.00102.x     Document Type: Article

References (25)

1. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-5.
2. NIH. Consensus Development Panel for Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-9.
3. Fock KM. Helicobacter pylori infection: Current status in Singapore. Ann Acad Med Singap 1997; 26: 637-41.
4. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
5. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of H. pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
6. Ministry of Health. Management of Helicobacter pylori infection. MOH Clinical Practice Guidelines 2/98. Singapore: Ministry of Health, 1998.
7. Lind T, Veldhuyzen van Zantan S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I Study. Helicobacter 1996; 1: 138-44.
8. Qasim A, O'Morain CA. Treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002; 16 (Suppl. 1): 24-30.
9. European Helicobacter pylori Study Group. Technical annex: Tests used to assess H. pylori infection. Working party of the European H. pylori Study Group. Gut 1997; 41 (Suppl. 2): S10-18.
10. Fock KM. Peptic ulcer in the 1990s: An Asian perspective. J Gastroenterol Hepatol 1997; 12: S23-8.
11. Hua J, Ng HC, Yeoh KG, Ho KY, Ho B. Characterisation of clinical isolates of Helicobacter pylori in Singapore. Microbios 1998; 94: 71-81.
12. Lind T, Megraud F, Unge P et al. The MACH2 Study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
13. Van der Wouden EJ, Thijs JC, van Zwet AA et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: A meta-analysis. Am J Gastroenterol 1999; 94: 1751-9.
14. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 7: 690-700.
15. Gisbert JP, Gisbert JL, Marcos S, Garcia Gravalos R, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-6.
16. Gomollon F, Duncos JA, Ferrero M et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton pump inhibitor based therapy: A detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999; 4: 222-5.
17. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-96.
18. Michopoulos S, Tsibouris P, Bouzakis H et al. Randomised study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000; 14: 737-44.
19. Georgopoulos SD, Ladas SD, Karatapanis S et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002; 16: 569-75.
20. Magaret N, Burm M, Faigel D et al. A randomised trial of lansoprazole, amoxyillin and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Dig Dis 2001; 19: 174-8.
21. Graham D, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
22. Graham DY. Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology 1998; 115: 1272-7.
23. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94: 725-9.
24. Perri F, Festa V, Clemente R et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 311-16.
25. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 2688-91.